# NCT00616109 (NCT00616109)

> Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00616109
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: University of Michigan Rogel Cancer Center
- Conditions: Extensive-Stage Small Cell Lung Cancer
- Interventions: sunitinib
- Enrollment: 16
- Primary outcome: Progression Free Survival Rate

## Indexed commentary on NCT00616109 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct00616109